Augma Biomaterials
Dental Bone Graft Materials
StartupAugma Biomaterials is a Caesarea-based startup in the Health Tech & Life Sciences sector, established in 2009. Dental Bone Graft Materials. The company has 11-50 employees. Core technologies: Materials & Substances, Implants.
The company follows a B2C/B2B business model. Product stage: Released.
- StageMature
- ProductReleased
- ModelB2C, B2B
- Employees11-50
- HQCaesarea
- DistrictCenter District
- Last RoundUndisclosed
1 article covered by sources including www.prnewswire.com.
What does Augma Biomaterials do?
Augma Biomaterials is dedicated to the development, production, and marketing of synthetic bone substitutes for the dental market. The companys 3D Bond (biphasic calcium sulfate) functions as a scaffold for bone regeneration in dental procedures and is intended to fill, augment, or reconstruct bony defects in the oral and maxillofacial region. Augmas Bond Apatite combines 3D Bond with a formula of hydroxyapatite granules to create a cement-based osteoconductive composite. Bond Apatite is a synthetic bone substitute used for bone reconstruction in a range of dental applications and is intended for filling, augmenting, and reconstructing a wide variety of defects in the maxillofacial bones. The product is FDA cleared and CE approved.
What sector is Augma Biomaterials in?
Augma Biomaterials operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Biomaterials & Tissue Engineering, with core technologies in Materials & Substances, Implants. Target customers: Healthcare & Life Sciences, Healthcare, Providers.
Where is Augma Biomaterials located?
Augma Biomaterials is based in Alon Hatavor 20, Keisarya, Israel, Center District. The company also has offices abroad.